AzTrials
AzTrials

LymphomaNCT07226934

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

A study testing GPT-QPL in people with Lymphoma and Multiple Myeloma, run by Washington University School of Medicine at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Lymphoma, Multiple Myeloma
What is being tested?
GPT-QPL
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteUnited States
Study dates
26 Dec 2025to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Eligibility Criteria as determined by Electronic Health Record (EHR) Screening:

  • Documented diagnosis of lymphoma, as defined by ICD-10 codes C81-C88 or multiple myeloma, as defined by ICD codes C90.0-C90.02
  • Has a scheduled follow-up appointment at a participating outpatient oncology clinic within the next month. Participating clinics include:
  • Dr. David Russler-Germain: Outpatient Lymphoma Clinic
  • Dr. Michael Slade: Outpatient Multiple Myeloma Clinic
  • Dr. Dilan Patel: Outpatient Lymphoma Clinic
  • Undergoing infusion or injection-based systemic therapy intended to cure or manage the disease, as opposed to regimens delivered solely for palliative purposes, at a frequency of once every 1-4 weeks.
  • For eligible patients with lymphoma, this includes, but is not limited to, commonly prescribed treatment combinations such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin/Hydroxydaunorubicin, Vincristine, and Prednisone) for Non-Hodgkin Lymphoma, or ABVD (Adriamycin/Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine) for Hodgkin Lymphoma-both regimens that are frequently administered every three weeks
  • For patients with multiple myeloma, eligibility will include patients in the "induction" phase of chemotherapy treatment, which frequently requires patients to come in for outpatient appointments once every four weeks as well as patients in a maintenance phase of treatment that otherwise requires them to attend outpatient appointments at a frequency of every one to four weeks
  • Between the ages of 18-99 at enrollment (Patients older than 99 will be excluded so that the study team is able to elicit questions from WashU ChatGPT using a standardized prompt that describes the patient's age only as specifically as a 10-year decade range (i.e., "I am a patient in my 20's, 30's, 40's, etc. Patients who are 18 or 19 years old will be described in the following manner: "I am a young adult patient in my late teens").
  • Able to consent to medical care independently (does not have a legally authorized representative or documented diagnosis of cognitive impairment)

Eligibility Criteria as determined by subsequent recruitment phone call or In-person approach after a clinic appointment:

  • Does not have visual impairments or English literacy limitations that would interfere with ability to engage in an intervention that requires being able to read material on an electronic device and on paper and communicate aloud during appointments with health care providers, based on patient self-report
  • Able to use email (consent form will be distributed electronically through DocuSign and associated emails), based on successful completion of electronic informed consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jessica Hahne, MA, MPH contact

314-935-6173

hahne.j@wustl.edu

United States1 site, 1 recruiting

  • Washington University School of Medicine

    St Louis, Missouri, 63110

    Jessica Hahne, MA, MPH, 314-935-6173, hahne.j@wustl.edu

    Jessica Hahne, MA, MPH

    Recruiting

Other trials in United States

About this study

Official title: Feasibility and Preliminary Efficacy of GPT-QPL: An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve tailoring a standardized prompt to patients' individual characteristics and concerns. This prompt will then be used to ask Washington University's (WashU) HIPAA compliant ChatGPT to generate personalized question lists for outpatient appointments. Analyses will assess the impact of personalized QPLs on patients' question-asking behavior; communicative self-efficacy; and self-reported amount and satisfaction with information obtained about their disease and its treatment. Sub-analyses will explore patterns in questions generated by WashU ChatGPT. Patients will also provide feedback pertaining to the perceived helpfulness and ease-of-use of WashU-ChatGPT-generated question lists, as well as their attitudes and intentions regarding use of AI chatbots and whether they would engage in pre-appointment AI-assisted question brainstorming independently in the future.

Being tested
GPT-QPL
Keywords
Generative Artificial Intelligence, Healthcare, Cancer, Communication
Medical subject headings
Lymphoma, Multiple Myeloma, Neoplasms, Communication

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GPT-QPLOther

    Also called AI-Generated, Personalized Question Prompt List

    A research team member will generate a QPL that is personalized to the patient's demographics (from EHR screening and Baseline Demographic Survey) and concerns (from Distress Thermometer Problem Checklist and Interview).

Study groups in NCT07226934
Study groupRoleWhat they receive
GPT-QPL: An AI-Generated, Personalized Question Prompt ListExperimentalParticipants will complete surveys at appointment 1 (pre-intervention) and after being provided the AI-Generated, Personalized Question Prompt List at appointment 2 (post-intervention).
Receives: Other: GPT-QPL

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in communicative self-efficacy

    • Communicative self-efficacy is measured by Self-efficacy survey .
    • Dependent samples t-tests will be used to assess within-subject changes.
    • The Self-Efficacy survey consists of two scales containing 10 questions each, with answers ranging from 1=not successful to 5=very successful or 1=not confident to 5=very confident. The total score on each scale ranges from 10-50 with a higher score on Scale 1 (the PEPPI-5) representing higher self-efficacy related to communicating with physicians in general and a higher score on Scale 2 (researcher-designed questions based on Social Cognitive Theory) representing higher self-perceived success at communication with the physician during the immediately preceding appointment.

    Measured: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

Secondary outcomes (4)

  1. Changes in perceived amount of cancer information received as measured by an abbreviated version the EORTC QLQ - INFO25

    • Dependent samples t-tests will be used to assess within-subject changes.
    • The abbreviated version of the EORTC QLQ-INFO 25 being used for this outcome consists of three scales containing a total of 13 questions ranging from 1=not at all to 4=very much. Raw scores are converted using linear transformations. The total score range for each scale is 0-100. A higher score on Scale 1 represents a higher perceived degree of information received about cancer diagnosis, a higher score on Scale 2 represents a higher perceived degree of information received about medical tests, and a higher score on Scale 3 represents a higher perceived degree of information received about cancer treatment.

    Measured: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

  2. Changes in satisfaction with cancer information received as measured by the EORTC QLQ - INFO25

    • Dependent samples t-tests will be used to assess within-subject changes.
    • An additional single item scale from the EORTC QLQ - INFO 25 will be used to measure satisfaction with cancer information received. The answer ranges from 1=not at all to 4=very much. The raw score is converted using the same linear transformation as other EORTC QLQ-INFO 25 scales. The total score range is 0-100, and a higher score represents higher satisfaction with cancer information received.

    Measured: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

  3. Changes in the number of questions asked during appointments

    • Number of questions asked is measured by audio recordings of the clinic appointments.
    • Dependent samples t-tests will be used to assess within-subject changes.

    Measured: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

  4. Changes in self-reported degree of intention to use AI chatbots for healthcare tasks

    • Self-reported degree of intention is measured by one-item AI Chatbot Use survey consisting of a 7-point Likert Scale question asking how frequently participants intend to use AI chatbots for healthcare tasks within the next month. The answer ranges from 1=Never to 7=Several times a day. The total score range is 1-7, and a higher score represents more frequent intended use of AI chatbots for healthcare tasks.
    • Dependent samples t-tests will be used to assess within-subject changes.

    Measured: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Nov 2025
  2. Study start26 Dec 2025
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07226934
Sponsor's protocol ID
202509134
Status last verified
Oct 2026
First submitted
7 Nov 2025
Last updated
8 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing GPT-QPL in people with Lymphoma and Multiple Myeloma, run by Washington University School of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jessica Hahne, MA, MPH (314-935-6173, hahne.j@wustl.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in communicative self-efficacy (time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07226934.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT07226934 | AzTrials